Experimental melanin-induced uveitis: Experimental model of human acute anterior uveitis

Justine R. Smith, James (Jim) Rosenbaum, Keryn A. Williams

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Experimental melanin-protein-induced uveitis (EMIU), which is also known as experimental autoimmune anterior uveitis, was first described in 1993 by Broekhuyse et al. This experimental uveitis may be induced in certain inbred and outbred rat strains by immunization with bovine ocular melanin. The inflammation shares clinical features with human acute anterior uveitis. The duration of the first episode is approximately 1 month. Spontaneous recovery to a near normal clinical state is the rule, but multiple recurrences are common. Slit-lamp biomicroscopic examination reveals a florid anterior-chamber reaction, with formation of a retro-iridal empyema, fibrin clots and posterior synechiae. At a microscopic level, leukocytic infiltration is first observed in the anterior uvea. Although this tissue remains the site of maximum inflammation throughout an attack, in severe cases, limbitis, vitritis and choroiditis are also observed. Abrogation of EMIU occurs after treatment with anti-CD4 antibody, indicating that the uveitis is controlled by CD4-positive T cells. Several research groups have used EMIU to investigate various aspects of the pathogenesis of acute anterior uveal inflammation, including the participation of different leukocyte subsets, the expression of cell adhesion molecules, cytokines, chemokines and nitric oxide, the role of complement and the impact of apoptosis. In addition, EMIU has also been used to evaluate various biologic interventions with potential implications for the treatment of human disease.

Original languageEnglish (US)
Pages (from-to)136-140
Number of pages5
JournalOphthalmic Research
Volume40
Issue number3-4
DOIs
StatePublished - Apr 2008

Fingerprint

Anterior Uveitis
Melanins
Uveitis
Theoretical Models
Inflammation
Proteins
Choroiditis
Uvea
Inbred Strains Rats
Empyema
Cell Adhesion Molecules
Anterior Chamber
Fibrin
Chemokines
Anti-Idiotypic Antibodies
Immunization
Nitric Oxide
Leukocytes
Apoptosis
Cytokines

Keywords

  • Experimental melanin-induced uveitis
  • Human acute anterior uveitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Experimental melanin-induced uveitis : Experimental model of human acute anterior uveitis. / Smith, Justine R.; Rosenbaum, James (Jim); Williams, Keryn A.

In: Ophthalmic Research, Vol. 40, No. 3-4, 04.2008, p. 136-140.

Research output: Contribution to journalArticle

@article{2b94271c732e45c291180b138e17f775,
title = "Experimental melanin-induced uveitis: Experimental model of human acute anterior uveitis",
abstract = "Experimental melanin-protein-induced uveitis (EMIU), which is also known as experimental autoimmune anterior uveitis, was first described in 1993 by Broekhuyse et al. This experimental uveitis may be induced in certain inbred and outbred rat strains by immunization with bovine ocular melanin. The inflammation shares clinical features with human acute anterior uveitis. The duration of the first episode is approximately 1 month. Spontaneous recovery to a near normal clinical state is the rule, but multiple recurrences are common. Slit-lamp biomicroscopic examination reveals a florid anterior-chamber reaction, with formation of a retro-iridal empyema, fibrin clots and posterior synechiae. At a microscopic level, leukocytic infiltration is first observed in the anterior uvea. Although this tissue remains the site of maximum inflammation throughout an attack, in severe cases, limbitis, vitritis and choroiditis are also observed. Abrogation of EMIU occurs after treatment with anti-CD4 antibody, indicating that the uveitis is controlled by CD4-positive T cells. Several research groups have used EMIU to investigate various aspects of the pathogenesis of acute anterior uveal inflammation, including the participation of different leukocyte subsets, the expression of cell adhesion molecules, cytokines, chemokines and nitric oxide, the role of complement and the impact of apoptosis. In addition, EMIU has also been used to evaluate various biologic interventions with potential implications for the treatment of human disease.",
keywords = "Experimental melanin-induced uveitis, Human acute anterior uveitis",
author = "Smith, {Justine R.} and Rosenbaum, {James (Jim)} and Williams, {Keryn A.}",
year = "2008",
month = "4",
doi = "10.1159/000119864",
language = "English (US)",
volume = "40",
pages = "136--140",
journal = "Ophthalmic Research",
issn = "0030-3747",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Experimental melanin-induced uveitis

T2 - Experimental model of human acute anterior uveitis

AU - Smith, Justine R.

AU - Rosenbaum, James (Jim)

AU - Williams, Keryn A.

PY - 2008/4

Y1 - 2008/4

N2 - Experimental melanin-protein-induced uveitis (EMIU), which is also known as experimental autoimmune anterior uveitis, was first described in 1993 by Broekhuyse et al. This experimental uveitis may be induced in certain inbred and outbred rat strains by immunization with bovine ocular melanin. The inflammation shares clinical features with human acute anterior uveitis. The duration of the first episode is approximately 1 month. Spontaneous recovery to a near normal clinical state is the rule, but multiple recurrences are common. Slit-lamp biomicroscopic examination reveals a florid anterior-chamber reaction, with formation of a retro-iridal empyema, fibrin clots and posterior synechiae. At a microscopic level, leukocytic infiltration is first observed in the anterior uvea. Although this tissue remains the site of maximum inflammation throughout an attack, in severe cases, limbitis, vitritis and choroiditis are also observed. Abrogation of EMIU occurs after treatment with anti-CD4 antibody, indicating that the uveitis is controlled by CD4-positive T cells. Several research groups have used EMIU to investigate various aspects of the pathogenesis of acute anterior uveal inflammation, including the participation of different leukocyte subsets, the expression of cell adhesion molecules, cytokines, chemokines and nitric oxide, the role of complement and the impact of apoptosis. In addition, EMIU has also been used to evaluate various biologic interventions with potential implications for the treatment of human disease.

AB - Experimental melanin-protein-induced uveitis (EMIU), which is also known as experimental autoimmune anterior uveitis, was first described in 1993 by Broekhuyse et al. This experimental uveitis may be induced in certain inbred and outbred rat strains by immunization with bovine ocular melanin. The inflammation shares clinical features with human acute anterior uveitis. The duration of the first episode is approximately 1 month. Spontaneous recovery to a near normal clinical state is the rule, but multiple recurrences are common. Slit-lamp biomicroscopic examination reveals a florid anterior-chamber reaction, with formation of a retro-iridal empyema, fibrin clots and posterior synechiae. At a microscopic level, leukocytic infiltration is first observed in the anterior uvea. Although this tissue remains the site of maximum inflammation throughout an attack, in severe cases, limbitis, vitritis and choroiditis are also observed. Abrogation of EMIU occurs after treatment with anti-CD4 antibody, indicating that the uveitis is controlled by CD4-positive T cells. Several research groups have used EMIU to investigate various aspects of the pathogenesis of acute anterior uveal inflammation, including the participation of different leukocyte subsets, the expression of cell adhesion molecules, cytokines, chemokines and nitric oxide, the role of complement and the impact of apoptosis. In addition, EMIU has also been used to evaluate various biologic interventions with potential implications for the treatment of human disease.

KW - Experimental melanin-induced uveitis

KW - Human acute anterior uveitis

UR - http://www.scopus.com/inward/record.url?scp=42449134976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449134976&partnerID=8YFLogxK

U2 - 10.1159/000119864

DO - 10.1159/000119864

M3 - Article

C2 - 18421227

AN - SCOPUS:42449134976

VL - 40

SP - 136

EP - 140

JO - Ophthalmic Research

JF - Ophthalmic Research

SN - 0030-3747

IS - 3-4

ER -